EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
ContributorsEULAR
Published inAnnals of the Rheumatic Diseases, vol. 76, no. 6, p. 960-977
Publication date2017
Abstract
Keywords
- Antibodies, Monoclonal/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/drug therapy
- Drug Substitution
- Drug Therapy, Combination
- Glucocorticoids/therapeutic use
- Humans
- Janus Kinases/antagonists & inhibitors
- Methotrexate/therapeutic use
- Patient Participation
- Protein Kinase Inhibitors/therapeutic use
- Time Factors
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
Affiliation entities
Research groups
Citation (ISO format)
EULAR. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. In: Annals of the Rheumatic Diseases, 2017, vol. 76, n° 6, p. 960–977. doi: 10.1136/annrheumdis-2016-210715
Main files (1)
Article (Published version)
Identifiers
- PID : unige:110657
- DOI : 10.1136/annrheumdis-2016-210715
- PMID : 28264816
ISSN of the journal0003-4967